Literature DB >> 21121855

Amenorrhea from breast cancer therapy--not a matter of dose.

Sandra M Swain, Jong-Hyeon Jeong, Norman Wolmark.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21121855     DOI: 10.1056/NEJMc1009616

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  22 in total

1.  Challenges of guarantee-time bias.

Authors:  Anita Giobbie-Hurder; Richard D Gelber; Meredith M Regan
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

Review 2.  Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

Authors:  S Gandhi; G G Fletcher; A Eisen; M Mates; O C Freedman; S F Dent; M E Trudeau
Journal:  Curr Oncol       Date:  2015-03       Impact factor: 3.677

3.  What Can We Learn From Menstrual Patterns After Treatment for HER2-Positive Breast Cancer?

Authors:  Elizabeth Cathcart-Rake; Kelly C Gast; Kathryn J Ruddy
Journal:  J Natl Cancer Inst       Date:  2019-01-01       Impact factor: 13.506

4.  Relationship between reproductive history, anthropometrics, lifestyle factors, and the likelihood of persistent chemotherapy-related amenorrhea in women with premenopausal breast cancer.

Authors:  Mary E Abusief; Stacey A Missmer; Elizabeth S Ginsburg; Jane C Weeks; Ann H Partridge
Journal:  Fertil Steril       Date:  2012-01       Impact factor: 7.329

5.  Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.

Authors:  Matteo Lambertini; Christine Campbell; José Bines; Larissa A Korde; Miguel Izquierdo; Debora Fumagalli; Lucia Del Mastro; Michail Ignatiadis; Kathleen Pritchard; Antonio C Wolff; Christian Jackisch; Istvan Lang; Michael Untch; Ian Smith; Frances Boyle; Binghe Xu; Carlos H Barrios; José Baselga; Alvaro Moreno-Aspitia; Martine Piccart; Richard D Gelber; Evandro de Azambuja
Journal:  J Natl Cancer Inst       Date:  2019-01-01       Impact factor: 13.506

6.  Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).

Authors:  Kathryn J Ruddy; Hao Guo; William Barry; Chau T Dang; Denise A Yardley; Beverly Moy; P Kelly Marcom; Kathy S Albain; Hope S Rugo; Matthew J Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beth A Overmoyer; Clifford Hudis; Ian E Krop; Harold J Burstein; Eric P Winer; Ann H Partridge; Sara M Tolaney
Journal:  Breast Cancer Res Treat       Date:  2015-05-16       Impact factor: 4.872

7.  Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.

Authors:  P Karlsson; Z Sun; D Braun; K N Price; M Castiglione-Gertsch; M Rabaglio; R D Gelber; D Crivellari; J Collins; E Murray; K Zaman; M Colleoni; B A Gusterson; G Viale; M M Regan; A S Coates; A Goldhirsch
Journal:  Ann Oncol       Date:  2011-02-16       Impact factor: 32.976

8.  Adjuvant ovarian suppression in premenopausal breast cancer.

Authors:  Prudence A Francis; Meredith M Regan; Gini F Fleming; István Láng; Eva Ciruelos; Meritxell Bellet; Hervé R Bonnefoi; Miguel A Climent; Gian Antonio Da Prada; Harold J Burstein; Silvana Martino; Nancy E Davidson; Charles E Geyer; Barbara A Walley; Robert Coleman; Pierre Kerbrat; Stefan Buchholz; James N Ingle; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Marco Colleoni; Giuseppe Viale; Alan S Coates; Aron Goldhirsch; Richard D Gelber
Journal:  N Engl J Med       Date:  2014-12-11       Impact factor: 91.245

9.  Hormonal therapies in young breast cancer patients: when, what and for how long?

Authors:  Alexandre Christinat; Simona Di Lascio; Olivia Pagani
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

10.  Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.

Authors:  A Goldhirsch; W C Wood; A S Coates; R D Gelber; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2011-06-27       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.